QL1604 Plus Chemotherapy Versus Chemotherapy in Subjects With Stage ⅣB, Recurrent, or Metastatic Cervical Cancer
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of PD-1 Inhibitor (QL1604)
plus chemotherapy in patients with Stage Ⅳ, recurrent, or metastatic cervical cancer.
Possible chemotherapy regimens include: paclitaxel plus cisplatin and paclitaxel plus
carboplatin.